Nintedanib Sandoz (Nintedanib)

Nintedanib blocks the activity of several receptor tyrosine kinases, including VEGFR, PDGFR and FGFR. By preventing these signals, the drug reduces fibroblast growth and new blood‑vessel formation, which are key processes in both fibrotic lung disease and tumor development.

The exact dose and dosing schedule are determined by the prescribing clinician based on the specific indication, patient characteristics and any concomitant therapies. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety data for nintedanib in pregnancy and lactation are limited, and the product is generally not recommended for use in pregnant or nursing women unless the potential benefit justifies the risk. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Nintedanib differs from other antifibrotics such as pirfenidone by targeting a broader range of tyrosine kinases, which may provide additional anti‑angiogenic activity. Clinical trials have shown comparable efficacy in slowing lung‑function decline, but the side‑effect profile and drug‑interaction potential vary, influencing choice based on patient tolerance and comorbidities.

Nintedanib Sandoz should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the product in its original packaging until use, and avoid storing it in bathrooms or other humid environments.

The medication is taken orally, usually as whole tablets swallowed with water. It is typically taken with food to reduce gastrointestinal discomfort, but patients should follow the specific instructions provided by their healthcare professional.

Serious risks include severe liver injury, major bleeding events, cardiovascular complications such as myocardial infarction, and rare gastrointestinal perforations. Patients should be monitored regularly for signs of liver dysfunction, bleeding, and cardiovascular symptoms, and any concerning signs should prompt immediate medical evaluation.

Nintedanib is contraindicated in patients with severe hepatic impairment, uncontrolled bleeding disorders, or known hypersensitivity to the drug. Caution is also advised for individuals with recent cardiovascular events, active gastrointestinal ulcers, or those taking strong CYP3A4 inhibitors.